In a patient with imaging‑confirmed atherosclerotic cardiovascular disease (ASCVD) but no prior cerebrovascular accident (stroke) or myocardial infarction (MI), what is the target low‑density lipoprotein (LDL) cholesterol level?

Goal LDL in Imaging-Confirmed ASCVD Without Prior CVA/MI

In patients with imaging-confirmed atherosclerotic cardiovascular disease (ASCVD) but no prior stroke or myocardial infarction, the target LDL cholesterol is <70 mg/dL (<1.8 mmol/L).

Rationale and Evidence Base

The most recent and authoritative guidance comes from the 2023 International Atherosclerosis Society recommendations 1, which explicitly address this clinical scenario. These guidelines distinguish between "clinical ASCVD" (prior MI, stroke, or symptomatic events) and "imaging evidence of ASCVD alone" – your patient falls into the latter category.

For imaging-documented ASCVD without clinical events, the LDL-C target is <70 mg/dL (<1.8 mmol/L) along with approximately 50% reduction from baseline 1. This is more aggressive than primary prevention but less stringent than the <55 mg/dL target reserved for patients with clinical ASCVD events.

What Qualifies as Imaging-Confirmed ASCVD

The ESC/EAS guidelines 2 specifically define imaging-confirmed ASCVD as:

• Coronary angiography or CT angiography: ≥2 major epicardial arteries with >50% stenosis
• Carotid ultrasound: Significant plaque burden
• CAC score >100: Reclassifies patients to high-risk status warranting LDL-C <70 mg/dL 2

This imaging evidence alone, without prior clinical events, places your patient in the "very high risk" category for European guidelines but would be considered high-risk (not very high-risk) in the AHA/ACC framework 2.

Critical Distinction: US vs European Guidelines

There's an important transatlantic divergence here 2:

• ESC/EAS approach: Imaging-documented ASCVD qualifies as "very high risk" → target LDL-C <55 mg/dL
• AHA/ACC 2018 approach: Only clinical ASCVD (prior MI, stroke, symptomatic PAD) qualifies for secondary prevention targets. Imaging findings alone remain in primary prevention algorithms → threshold of ≥70 mg/dL for treatment intensification

The 2024 International Lipid Expert Panel (ILEP) recommendations 3 bridge this gap by endorsing the <70 mg/dL target for imaging-confirmed ASCVD, aligning more closely with European practice while acknowledging US guideline structures.

Treatment Algorithm

Initial Therapy

1. Start high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) 1
2. Measure LDL-C at 4-6 weeks to assess response

If LDL-C Remains ≥70 mg/dL (≥1.8 mmol/L)

1. Add ezetimibe 10 mg daily 1, 4
   • This combination typically achieves an additional 15-20% LDL-C reduction
   • Reassess in 4-6 weeks

If LDL-C Still ≥70 mg/dL on Statin + Ezetimibe

1. Consider PCSK9 inhibitor (evolocumab or alirocumab) 1, 4
   • Canadian guidelines 4 support this threshold of ≥70 mg/dL (≥1.8 mmol/L) for PCSK9i addition
   • Achieves an additional 50-60% LDL-C reduction
   • Note: Access may be limited by insurance coverage in many jurisdictions

Common Pitfalls to Avoid

1. Don't dismiss imaging findings as "subclinical": The presence of significant atherosclerotic plaque on imaging represents established disease requiring aggressive management, even without prior events 2

2. Don't delay treatment intensification: Real-world data 5, 6, 7 consistently show that only 21-40% of ASCVD patients achieve guideline-recommended LDL-C targets, largely due to therapeutic inertia. If LDL-C is not at goal after 4-6 weeks, intensify therapy immediately rather than waiting for an event to occur.

3. Don't confuse this with primary prevention: While AHA/ACC guidelines 8 technically classify imaging-only ASCVD as primary prevention, the presence of anatomic disease warrants more aggressive treatment than risk-score-based primary prevention.

4. Consider upfront combination therapy: The 2024 ILEP recommendations 3 suggest that in patients with very high baseline LDL-C, starting with statin + ezetimibe combination (ideally as fixed-dose combination for adherence) may be more effective than sequential titration.

Special Considerations

If your patient also has diabetes or metabolic syndrome: Consider pitavastatin-based regimens or lower-dose high-intensity statins with ezetimibe to balance LDL-C lowering with minimizing new-onset diabetes risk 3.

Secondary targets 1: If triglycerides are elevated, consider non-HDL-C <100 mg/dL or ApoB <80 mg/dL as alternative targets.